Please assess the completion status of the following clinical trial:

Trial Title: Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed and dated informed consent prior to any study specific procedures.~2. Males aged ≥ 40 and ≤ 75 years and post-menopausal women (defined as at least 1 year post cessation of menses) aged ≥ 50 and ≤ 75 years~3. Body mass index (BMI) ≥ 27 and ≤ 38 kg/m2.~4. Sedentary lifestyle (not more than 3 hours of programmed exercise per week).~5. Stable dietary habits.~6. Impaired glucose homeostasis based on one or a combination of the following criteria:~   * Impaired Glucose Tolerance (IGT): plasma glucose values ≥ 7.8 mmol/l and ≤ 11.1 mmol/l 120 minutes after consumption of the glucose drink during the 2h, 3-point OGTT.~  * Impaired Fasting Glucose (IFG): fasting plasma glucose ≥ 6.1 mmol/l and ≤ 6.9 mmol/l.~  * Insulin Resistance: glucose clearance rate ≤ 360 ml/kg/min, as calculated by Oral Glucose Insulin Sensitivity 120 (OGIS120) model based on the 2h, 3-point OGTT.~  * HbA1c ≥ 5.7% and ≤ 6.4%.~Exclusion Criteria:~1. Clinical diagnosis of Type 1 or 2 Diabetes Mellitus.~2. Active cardiovascular disease: participants who experienced a heart attack in the last year, or participants who are currently under regular control of a physician for a heart condition.~3. Weight gain or loss \> 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents.~4. Regular smoking and other regular nicotine use.~5. Anaemia.~6. Uncontrolled hypertension.~7. Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) in the Investigator's opinion.~8. Unstable or rapidly progressing renal disease or estimated Glomerular Filtration Rate (eGFR) \<60 mL/min (Cockcroft-Gault formula).~9. Use of anti-coagulant treatment and other concomitant medication will be evaluated on a case to case basis with a general physician.~10. Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity.~11. Use of loop diuretics.~12. Intake of dietary supplements except multi-vitamins and minerals.~13. Alcohol consumption of \> 14 drinks per week for women and \> 21 drinks per week for men (1 drink = 35 cl beer, 14 cl wine or 4 cl hard liquor).~14. Known hypersensitivity to dapagliflozin or any of the excipients of the product.~15. For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.~16. Participation in another biomedical study within 1 month before the screening visit.~17. Any contraindication for MRI scanning.~18. Participants who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Dapagliflozin 10 mg (Type: ACTIVE_COMPARATOR): Patients will receive dapagliflozin 10 mg in tablet for a maximum of 14 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 14 days.
- Placebo matching to dapagliflozin 10 mg (Type: PLACEBO_COMPARATOR): Patients will receive matching placebo in tablet for a maximum of 14 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).